Viral Infection and Lung Cancer Immunotherapy

Viral Infection and Lung Cancer Immunotherapy

Immunotherapy with immune checkpoint inhibitors (mainly anti-PD1 and anti-PDL1 monoclonal antibodies) became a standard of care in non-small cell lung cancer (NSCLC) patients. Most of the clinical trials excluded patients with hepatitis B (HBV), hepatis C (HCV), and human immunodeficiency virus (HIV...

Full description

Bibliographic Details
Main Authors: Ewa Kalinka, Izabela Chmielewska, Kamila Wojas-Krawczyk
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
lung cancer
immunotherapy
HBV
HCV
HIV
SARS-Cov-2
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.577514/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.577514/full

Similar Items